BBIO - BridgeBio Pharma, Inc.
31.57
-0.660 -2.091%
Share volume: 3,266,247
Last Updated: 03-07-2025
Pharmaceutical Products/Pharmaceutical Preparations:
0.03%
PREVIOUS CLOSE
CHG
CHG%
$32.23
-0.66
-0.02%
Fundamental analysis
30%
Profitability
15%
Dept financing
25%
Liquidity
58%
Performance
40%
Performance
5 Days
-2.05%
1 Month
1.45%
3 Months
8.94%
6 Months
12.79%
1 Year
9.09%
2 Year
117.27%
Key data
Stock price
$31.57
DAY RANGE
$31.22 - $32.64
52 WEEK RANGE
$21.62 - $39.47
52 WEEK CHANGE
$10.00
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail

CEO: Neil Kumar
Region: US
Website: bridgebio.com
Employees: 400
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: bridgebio.com
Employees: 400
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a stabilizer of transthyretin, or TTR.
Recent news